• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.头孢洛扎坦-他唑巴坦和头孢他啶-阿维巴坦对一组耐β-内酰胺革兰氏阴性菌的敏感性
Ann Lab Med. 2017 Mar;37(2):174-176. doi: 10.3343/alm.2017.37.2.174.
2
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.头孢洛扎/他唑巴坦与头孢他啶/阿维巴坦对大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌多重耐药菌株抗菌活性的比较。
Int J Infect Dis. 2017 Sep;62:39-43. doi: 10.1016/j.ijid.2017.06.007. Epub 2017 Jun 10.
3
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.头孢他洛滨-他唑巴坦和头孢他啶-阿维巴坦对β-内酰胺类耐药铜绿假单胞菌分离株的活性。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01858-17. Print 2017 Dec.
4
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对耐美罗培南铜绿假单胞菌分离株的体外活性评估。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
5
Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.碳青霉烯类耐药肠杆菌科细菌和铜绿假单胞菌中头孢他啶-阿维巴坦和头孢唑南-他唑巴坦药敏检测方法的验证。
J Clin Microbiol. 2018 Jan 24;56(2). doi: 10.1128/JCM.01093-17. Print 2018 Feb.
6
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.耐哌拉西林/他唑巴坦铜绿假单胞菌对头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦和碳青霉烯类药物耐药性的系统进化分析。
Int J Antimicrob Agents. 2019 Jun;53(6):774-780. doi: 10.1016/j.ijantimicag.2019.02.022. Epub 2019 Mar 2.
7
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.多中心评估头孢他啶-阿维巴坦和头孢洛扎坦-他唑巴坦对血液、呼吸道和伤口来源的美罗培南不敏感铜绿假单胞菌的抑制活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
8
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.2012年和2013年在美国医疗中心分离出的对多药耐药铜绿假单胞菌的头孢他啶-阿维巴坦活性。
Antimicrob Agents Chemother. 2015;59(6):3656-9. doi: 10.1128/AAC.05024-14. Epub 2015 Apr 6.
9
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.体外研究头孢洛扎他唑巴坦和头孢他啶-阿维巴坦对耐美罗培南铜绿假单胞菌临床分离株的活性：一项多中心研究。
J Glob Antimicrob Resist. 2020 Mar;20:334-338. doi: 10.1016/j.jgar.2019.09.016. Epub 2019 Sep 27.
10
Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.头孢他啶/阿维巴坦对重症监护病房（ICU）和非 ICU 患者的革兰氏阴性菌进行了测试，包括呼吸机相关性肺炎患者。
Int J Antimicrob Agents. 2015 Jul;46(1):53-9. doi: 10.1016/j.ijantimicag.2015.02.022. Epub 2015 Apr 14.

引用本文的文献

1
Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.革兰氏阴性菌对头孢他啶-阿维巴坦耐药性的全球趋势：系统评价与荟萃分析
Antimicrob Resist Infect Control. 2025 Feb 11;14(1):10. doi: 10.1186/s13756-025-01518-5.
2
In vitro activity of ceftazidime-avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains.头孢他啶-阿维巴坦/氨曲南联合用药对产金属β-内酰胺酶铜绿假单胞菌菌株的体外活性
Infection. 2024 Nov 18. doi: 10.1007/s15010-024-02425-4.
3
Satisfactory In Vitro Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant But Not against Isolates.头孢洛扎他唑巴坦对碳青霉烯类耐药但对非耐药分离株具有满意的体外活性。
Medicina (Kaunas). 2023 Mar 7;59(3):518. doi: 10.3390/medicina59030518.
4
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.头孢他啶/他唑巴坦与美罗培南治疗复杂性尿路感染（包括肾盂肾炎）新生儿和儿童的安全性和疗效：一项 2 期随机临床试验。
Pediatr Infect Dis J. 2023 Apr 1;42(4):292-298. doi: 10.1097/INF.0000000000003832. Epub 2023 Jan 23.
5
Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.氟喹诺酮类杂化分子作为对抗抗菌耐药性的有前景的抗菌剂。
Pharmaceutics. 2022 Aug 22;14(8):1749. doi: 10.3390/pharmaceutics14081749.
6
Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.含头孢他啶-阿维巴坦的抗生素组合对广泛耐药铜绿假单胞菌的时间杀菌评估及其对头孢他啶-阿维巴坦耐药分离株的潜在作用。
Microbiol Spectr. 2021 Sep 3;9(1):e0058521. doi: 10.1128/Spectrum.00585-21. Epub 2021 Jul 28.
7
Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective.脓毒症患者及严重感染中的新型头孢菌素：当前研究结果与未来展望
Front Med (Lausanne). 2021 May 7;8:617378. doi: 10.3389/fmed.2021.617378. eCollection 2021.
8
New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam.抗菌药物新视角：头孢他洛巴坦-他唑巴坦。
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0231820. doi: 10.1128/AAC.02318-20.
9
Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 study.评估头孢洛扎-他唑巴坦对来自巴西的近期临床分离菌的体外活性 - EM200 研究。
Braz J Infect Dis. 2020 Mar-Apr;24(2):96-103. doi: 10.1016/j.bjid.2020.04.004. Epub 2020 Apr 28.
10
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.评估头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦对来自卡塔尔的多重耐药铜绿假单胞菌分离株的体外活性。
J Antimicrob Chemother. 2019 Dec 1;74(12):3497-3504. doi: 10.1093/jac/dkz379.

本文引用的文献

1
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对耐美罗培南铜绿假单胞菌分离株的体外活性评估。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
2
Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.头孢洛扎/他唑巴坦：一种新型头孢菌素与β-内酰胺酶抑制剂的组合。
Ann Pharmacother. 2015 Sep;49(9):1046-56. doi: 10.1177/1060028015593293. Epub 2015 Jul 9.
3
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.2012年和2013年在美国医疗中心分离出的对多药耐药铜绿假单胞菌的头孢他啶-阿维巴坦活性。
Antimicrob Agents Chemother. 2015;59(6):3656-9. doi: 10.1128/AAC.05024-14. Epub 2015 Apr 6.
4
In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.体外研究显示，头孢洛扎-他唑巴坦对 2010 至 2011 年美国产携带 CTX-M 型超广谱β-内酰胺酶的大肠埃希菌的体外活性，通过肉汤稀释法和琼脂扩散法进行检测。
J Clin Microbiol. 2014 Nov;52(11):4049-52. doi: 10.1128/JCM.02357-14. Epub 2014 Aug 20.
5
Multi-center evaluation of the VITEK® MS system for mass spectrometric identification of non-Enterobacteriaceae Gram-negative bacilli.VITEK® MS系统用于非肠杆菌科革兰氏阴性杆菌质谱鉴定的多中心评估
Eur J Clin Microbiol Infect Dis. 2014 Mar;33(3):337-46. doi: 10.1007/s10096-013-1961-2. Epub 2013 Sep 10.
6
Identification of Enterobacteriaceae by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the VITEK MS system.采用 VITEK MS 系统的基质辅助激光解吸/电离飞行时间质谱法鉴定肠杆菌科。
Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1571-8. doi: 10.1007/s10096-013-1912-y. Epub 2013 Jul 2.
7
Detection of Klebsiella pneumoniae carbapenemase (KPC) production in non-Klebsiella pneumoniae Enterobacteriaceae isolates by use of the Phoenix, Vitek 2, and disk diffusion methods.采用 Phoenix、Vitek 2 和纸片扩散法检测非肺炎克雷伯菌肠杆菌科分离株中产碳青霉烯酶的肺炎克雷伯菌（KPC）。
J Clin Microbiol. 2011 Mar;49(3):1143-7. doi: 10.1128/JCM.02163-10. Epub 2011 Jan 5.

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.

作者信息

Gonzalez Mark D, McMullen Allison R, Wallace Meghan A, Crotty Matthew P, Ritchie David J, Burnham Carey Ann D

机构信息

Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USA.

Department of Laboratory Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA.

出版信息

Ann Lab Med. 2017 Mar;37(2):174-176. doi: 10.3343/alm.2017.37.2.174.

DOI:10.3343/alm.2017.37.2.174
PMID:28029009
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5204000/
Abstract
摘要